Remove 2030 Remove Compounding Remove Packaging
article thumbnail

Advancements in Biopharma Spur Innovation

PharmTech

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage 52
article thumbnail

Cell and gene therapy: The vital role of logistics

Pharmaceutical Technology

The projected growth of the cell and gene therapy market GlobalData estimates that the cell and gene therapy market will achieve global sales of $76.03bn by 2030, up from $5.88bn in 2023, with a compound annual growth rate (CAGR) of 44% over the seven years analysed. How will RFK Jr’s American dream for vaccines play out?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Elkedonia Raises €11.25M Seed Round to Advance Neuroplastogen Therapy for Depression

PharmTech

The financing round was co-led by Kurma Partners , WE Life Sciences , and the French Tech Seed Fund managed by Bpifrance , on behalf of the French government, under the France 2030 initiative. Additional participants included Argobio , Angelini Ventures , CARMA Fund , Capital Grand Est , and Sambrinvest.

Dosage 52
article thumbnail

Pharma contract manufacturing market to grow to $130bn by 2026

European Pharmaceutical Review

percent compound annual growth rate (CAGR) of the market include the increasing commercialisation of generics and emerging technologies and small biotechs with limited or no production capabilities driving development in the biopharmaceutical sector. According to the report, the packaging segment of the market will be worth $15.6

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. In the context of CO 2 neutrality, the years 2030 and 2050 are mentioned as crucial milestones.

article thumbnail

Challenges for Net Zero Carbon Pharmaceutical Manufacturing

ISPE

C global warming scenario by 2030, which is widely acknowledged to be necessary to avoid the worst impacts of climate change. solvent selection, inhaler propellant replacement, and packaging design) to employee travel and commute policy (e.g., recycled content in packaging, reduction of packaging weights).

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™